Zynerba Pharma (ZYNE) Reports Q2 Loss of $0.70/Share
- Futures falter as Meta Platforms weighs on megacaps
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Zynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational Changes
August 11, 2016 7:15 AM EDTJim Fickenscher will assume role as Chief Financial Officer, VP, Corporate Development
Dr. Nancy Tich appointed VP, Clinical, in a newly created position
DEVON, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:... More